Charles Cohn, MD
Internal Medicine · Sandy Springs, GANPI 1538168232
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 314 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 22.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,312 and has fallen 58.8% since, to $540 in 2025. Among internal medicine clinicians in GA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 314 payments — averaging $16.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Sanofi-aventis U.S. LLC$722
- AstraZeneca$620
- Amgen$367
- Lilly USA, LLC$345
- AbbVie$276
- plus $2K from 23 others
What the payments were for
- Food & beverage$5,26199%
- Education$321%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 66 | $1,200 |
| Sanofi-aventis U.S. LLC | 41 | $722 |
| AstraZeneca | 43 | $620 |
| Amgen | 24 | $367 |
| Lilly USA, LLC | 23 | $345 |
| AbbVie | 18 | $276 |
| Kowa Pharmaceuticals America, Inc. | 17 | $240 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $207 |
| Merck | 13 | $194 |
| Amarin Pharma, Inc. | 9 | $174 |
| Pfizer | 7 | $147 |
| Atricure, Inc. | 1 | $142 |
| Boehringer Ingelheim | 8 | $128 |
| Astellas Pharma US Inc | 6 | $109 |
| Exact Sciences | 3 | $56 |
| GSK | 3 | $45 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $41 |
| Sanofi Pasteur Inc. | 2 | $35 |
| Esperion Therapeutics, Inc. | 2 | $31 |
| Biohaven Pharmaceuticals, Inc. | 2 | $31 |
| Ironwood Pharmaceuticals, Inc | 2 | $30 |
| Radius Health, Inc. | 2 | $30 |
| Eisai Inc. | 2 | $23 |
| Abbott | 1 | $22 |
| Sumitomo Pharma America, Inc. | 1 | $22 |
| Bayer | 1 | $17 |
| Phathom Pharmaceuticals, Inc. | 1 | $15 |
| Shire North American Group Inc | 1 | $12 |
| Next Science LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$240
- SYNERGY ABLATION SYSTEM$142
How this compares
$5,293 in reported general payments places this provider in the 90th percentile of 3,311 internal medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 94 | $104,594 |
| JardianceEmpagliflozin | 99 | $85,278 |
| FarxigaDapagliflozin Propanediol | 74 | $74,945 |
| OzempicSemaglutide | 68 | $73,862 |
| RybelsusSemaglutide | 19 | $38,706 |
| XareltoRivaroxaban | 20 | $28,244 |
| JanuviaSitagliptin Phosphate | 35 | $26,597 |
| MyrbetriqMirabegron | 15 | $16,451 |
| LinzessLinaclotide | 17 | $16,205 |
| Repatha SureclickEvolocumab | 11 | $14,689 |
| TrulicityDulaglutide | 15 | $13,919 |
| Breo ElliptaFluticasone/Vilanterol | 27 | $12,491 |
| NexletolBempedoic Acid | 18 | $11,713 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 12 | $7,157 |
| Atorvastatin Calcium | 639 | $5,603 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $345 | $118,514109 claims |
| Novo NordiskOzempic, Rybelsus | $1,200 | $112,56887 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $128 | $92,436111 claims |
| AstraZenecaFarxiga, Symbicort | $620 | $78,57987 claims |
| MerckJanuvia | $194 | $26,59735 claims |
| AbbVieLinzess, Synthroid | $276 | $19,62267 claims |
| Astellas Pharma US IncMyrbetriq | $109 | $16,45115 claims |
| GSKBreo Ellipta | $45 | $12,49127 claims |
| Esperion Therapeutics, Inc.Nexletol | $31 | $11,71318 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,311 internal medicine providers in Georgia.
Other internal medicine in Sandy Springs
- Michael GibsonSmyrna$2.2M
- Eduard FatakhovAlpharetta$376K
- Tracey HenryAtlanta$305K
- Sharon TuckettVilla Rica$265K
- Ebon BourneMarietta$242K
- Jennifer WoehlerSavannah$207K
- Julian HutchinsGreensboro$201K
- Brian PearlmanDalton$199K
- Scott ParryAtlanta$162K
- Jennifer GilliganAtlanta$162K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.